Intra-Cellular Therapies (ITCI) News Today $131.87 0.00 (0.00%) As of 04/2/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period StockNews.com Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)April 21 at 2:11 AM | americanbankingnews.comRep. Josh Gottheimer Sells Off Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)April 14, 2025 | americanbankingnews.comFmr LLC Reduces Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Fmr LLC lessened its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,076,445 shares of the biopharmaceutical company's stockApril 10, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Sells Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) SharesRepresentative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Intra-Cellular Therapies stock on March 24th. The trade ocApril 10, 2025 | marketbeat.comGeode Capital Management LLC Has $143.43 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Geode Capital Management LLC grew its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,716,829 shares of the biopharmaceutical company'April 9, 2025 | marketbeat.comAtika Capital Management LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Atika Capital Management LLC lowered its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 12.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,000 shares of the biopharmaceApril 8, 2025 | marketbeat.comRhenman & Partners Asset Management AB Has $14.70 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Rhenman & Partners Asset Management AB reduced its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 14.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 176,000 shares of the biophApril 7, 2025 | marketbeat.comTrexquant Investment LP Has $4.39 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Trexquant Investment LP reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 47.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,585 shares of the biopharmaceutical comApril 7, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Wellington Management Group LLPWellington Management Group LLP raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,033,743 shares of the biopharmaceutical company's stoApril 7, 2025 | marketbeat.comCalifornia Public Employees Retirement System Has $13.76 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)California Public Employees Retirement System decreased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 2.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 164,712 shaApril 7, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.comStockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Saturday. They issued a "hold" rating for the company.April 6, 2025 | marketbeat.comAlliancebernstein L.P. Sells 151,818 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Alliancebernstein L.P. lessened its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 12.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,056,520 shares of the biopharmaceutical compApril 5, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Position Lowered by Orion Portfolio Solutions LLCOrion Portfolio Solutions LLC lowered its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,739 shares of the biophApril 5, 2025 | marketbeat.comPromising Pharmaceutical Stocks To Add to Your Watchlist - April 2ndIntra-Cellular Therapies, Eli Lilly and Company, Johnson & Johnson, AbbVie, Thermo Fisher Scientific, Pfizer, and Merck & Co., Inc. are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies involved in the researApril 4, 2025 | marketbeat.comMedical Stocks To Keep An Eye On - April 2ndIntra-Cellular Therapies, Eli Lilly and Company, and Walmart are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares in companies that operate within the healthcare industry, including pharmaceuticals, biotechnology firms, medical deviceApril 4, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Receives Neutral Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed a "neutral" rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday.April 4, 2025 | marketbeat.comCynosure Group LLC Decreases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Cynosure Group LLC lowered its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 24.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,841 shares of the biopharmaceutical company's stockApril 4, 2025 | marketbeat.comFranklin Resources Inc. Purchases 23,594 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Franklin Resources Inc. raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,776,880 shares of the biopharmaceuticApril 4, 2025 | marketbeat.comB. Metzler seel. Sohn & Co. AG Sells 14,986 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)B. Metzler seel. Sohn & Co. AG reduced its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 45.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,305 shares of the biophApril 4, 2025 | marketbeat.comHeadlands Technologies LLC Buys 2,883 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Headlands Technologies LLC raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 17.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,065 shares of the biopharmaceutical cApril 3, 2025 | marketbeat.comIntra-Cellular Therapies (ITCI) Receives a Rating Update from a Top AnalystApril 3, 2025 | markets.businessinsider.com5ITCI : Demystifying Intra-Cellular Therapies: Insights From 6 Analyst...April 2, 2025 | benzinga.comAxiom Investors LLC DE Has $5.02 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Axiom Investors LLC DE lessened its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,101 shares of the biopharmacApril 2, 2025 | marketbeat.comSchroder Investment Management Group Reduces Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Schroder Investment Management Group reduced its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 19.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 743,230 shares of the biopharmaceutical company's stock after selling 180,April 2, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Reaches New 1-Year High - Time to Buy?Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 52-Week High - Here's What HappenedApril 1, 2025 | marketbeat.comClearbridge Investments LLC Sells 43,345 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Clearbridge Investments LLC trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,686,384 shares of the biopharmacApril 1, 2025 | marketbeat.comDnB Asset Management AS Trims Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)DnB Asset Management AS lowered its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 10.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,569 shares of the biopharmaceutical comApril 1, 2025 | marketbeat.comNorges Bank Makes New $268.35 Million Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Norges Bank acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 3,212,964 shares of the biopharmaceutical company's stock, valued at approxiMarch 31, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Position Decreased by JPMorgan Chase & Co.JPMorgan Chase & Co. decreased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,126,092 shares of the biopharmaceutical company's stock afteMarch 31, 2025 | marketbeat.comVanguard Group Inc. Grows Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Vanguard Group Inc. raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,721,360 shares of the biopharmaceuticMarch 31, 2025 | marketbeat.comAmerican Century Companies Inc. Raises Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)American Century Companies Inc. increased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 25.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 314,362 shares ofMarch 31, 2025 | marketbeat.comPictet Asset Management Holding SA Has $128.66 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Pictet Asset Management Holding SA reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owneMarch 30, 2025 | marketbeat.comKLP Kapitalforvaltning AS Makes New $1.71 Million Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)KLP Kapitalforvaltning AS bought a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 20,500 shares of the biopharmaceutical company'March 30, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Recommendation of "Hold" by AnalystsIntra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) has been assigned a consensus recommendation of "Hold" from the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation, five have gMarch 30, 2025 | marketbeat.comIntra-Cellular TherapiesMarch 29, 2025 | forbes.comSei Investments Co. Acquires 14,379 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Sei Investments Co. boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 7.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,806 shares of the biopharmacMarch 29, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.comStockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Friday. They set a "hold" rating on the stock.March 28, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Teacher Retirement System of TexasTeacher Retirement System of Texas boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 18.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 28,159 shares of the biopharmaceutical company's stock after purchasing an aMarch 27, 2025 | marketbeat.comEFG Asset Management North America Corp. Purchases 37,061 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)EFG Asset Management North America Corp. grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 99.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,190 shares of the biopharmaMarch 26, 2025 | marketbeat.comIntra-Cellular Therapies (NASDAQ:ITCI) Reaches New 12-Month High - Time to Buy?Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 12-Month High - Here's WhyMarch 25, 2025 | marketbeat.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Emerald Advisers LLCEmerald Advisers LLC reduced its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 438,066 shares of thMarch 24, 2025 | marketbeat.comSimplify Asset Management Inc. Has $1.69 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Simplify Asset Management Inc. lowered its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 34.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,268 shares ofMarch 24, 2025 | marketbeat.comFox Run Management L.L.C. Purchases Shares of 16,667 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Fox Run Management L.L.C. purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 16,667 shares of the biopharmaceutical company's stock, valued at approximMarch 23, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 7,488 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 43.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,61March 22, 2025 | marketbeat.comIntra-Cellular Therapies announces proxy statement supplementMarch 20, 2025 | uk.investing.comPrivium Fund Management B.V. Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Privium Fund Management B.V. decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 17.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 97,154 shares of the biopharmaceutical company's stock afMarch 20, 2025 | marketbeat.comProficio Capital Partners LLC Invests $1.59 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)Proficio Capital Partners LLC bought a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 19,043 shares of the biopharmaceutical company'sMarch 20, 2025 | marketbeat.comIntra-Cellular Therapies Stock Hits All-Time High of $131.47March 18, 2025 | investing.comIs Intra-Cellular Therapies, Inc. (ITCI) a Best Biotech Stock According to Billionaires?March 18, 2025 | msn.comIntra-Cellular Therapies (NASDAQ:ITCI) Sets New 12-Month High - Time to Buy?Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 52-Week High - Here's WhyMarch 18, 2025 | marketbeat.com Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Media Mentions By Week ITCI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITCI News Sentiment▼0.000.73▲Average Medical News Sentiment ITCI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITCI Articles This Week▼18▲ITCI Articles Average Week Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TAK News ARGX News BNTX News ONC News SMMT News TEVA News GMAB News RDY News ASND News MRNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITCI) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ITCI Stock Free ITCI Stock Alerts